Lowest Price Guaranteed From USD 4,899
Published
September 2020
Pages
220
View Count
6754
Example Insights
Report Description
Over the years, technological advances in the field of genomics have enabled pharma companies to adopt a more personalized and targeted approach to drug / therapy development. Specifically, next-generation sequencing (NGS) technologies have enabled millions of human genomes across diverse ethnicities, to be sequenced. The large volumes of genomic data from the aforementioned sequencing studies have led to the generation of valuable insights on individuals' likely responses to different treatment regimens. Innovation in this field have made NGS technologies increasingly affordable and accessible. In fact, the cost of sequencing a single genome has dropped from USD ~3 billion (Human Genome Project 1990) to USD 1,000 (Illumina sequencing kits) over the last two decades. However, NGS based analyses are limited to offering averaged insights on gene expression. In other words, this method is incapable of quantifying nucleic acid content in individual cells, and thereby, offering gene expression information at single cell resolution. To better understand the interactions of individual cells with their microenvironment, advanced molecular probing solutions are required. In this context, high-throughput single-cell analysis, an emerging analytical technique, is considered a powerful means for studying individual cells, enabling researchers to study gene expression at single cell resolution.
Single-cell sequencing techniques offer many advantages over traditional genomic analyses, enabling the detection of complex and rare cell populations, and elucidating development trajectories of distinct cell lineages. Despite the potential to be used across diverse segments in biotechnology and medical research, this technique is still limited to early-stage research activities. This is primarily attributed to certain challenges associated with data processing and quality control. Further, the lack of versatile in silico tools is also considered among the major roadblocks to meaningful analysis and interpretation of single cell sequencing data. Additionally, the high cost of process execution and affiliated labor intensive protocols are other barriers to the adoption of since-cell sequencing technology. However, the introduction of the RNA-QC-Chain tool in 2018 (an effort to address the data processing and quality control related challenges) and the Human Cell Atlas project (responsible for developing the first whole transcriptome map of human cells), are considered prominent milestones in the field of single cell genomics. Presently, experts believe that the single-cell genomics market in North America, may reach USD 5 billion by 2025. Given, the potential of single-cell RNA sequencing (scRNA-seq) technologies to probe into previously unelucidated cellular mechanisms, and identify novel biomarkers / therapeutic targets, they are likely to witness significant adoption in biomedical research over the next decade.
The ‘Single-cell Sequencing Services and Technologies Market, 2020-2030’ report features an extensive study of the current landscape and the future opportunities associated with single-cell sequencing services / technologies. In addition to other elements, the report features:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as number of single-cell samples sequenced annually, average cost of sequencing, and growth trends across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2020-2030. The chapter features the likely distribution of the opportunity across different [A] key market segments (services and technologies), [B] type of system (sequencing and workflow instruments), [C] end-user (pharmaceutical companies, academic and research institutions and other end-users), [D] area of application (diagnostics, drug discovery, precision medicine and others) and [E] geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the single-cell sequencing market in the mid to long term.
Chapter 3 provides an overview of single-cell sequencing, and the process involved in single-cell sequencing and analysis. It also highlights different applications of single-cell sequencing in life sciences, specifically in cancer research, clinical diagnostics, drug discovery, embryology, immunology, microbiology, neurology and organ development. Further, the chapter highlights the key challenges associated with the adoption of single-cell sequencing and its future perspectives.
Chapter 4 provides an overview of the competitive landscape of single-cell sequencing service providers, including a detailed analysis based on parameters, such as year of establishment, company size, geographical location, sequencing method used (DNA sequencing, RNA sequencing, ATAC sequencing and DNA methylation), types of service offered (library preparation, sequencing and bioinformatics), types of library preparation system used and types of sequencing system used.
Chapter 5 provides an overview of the market landscape of single-cell sequencing workflow instruments, including an analysis based on parameters, such as type of target nucleic acid (DNA, RNA and protein), type of application (cell isolation, cDNA amplification and library preparation) and throughput. In addition, the report features study of market landscape of single-cell sequencing systems providing information on parameters, such as type of application (single-cell, whole genome, whole exome and targeted sequencing), maximum output, maximum read length, system efficiency, sequencing chemistry (sequencing-by-synthesis, SMRT sequencing and nanopore sequencing), year of establishment, company size and geographical location. It also includes an analysis on the companies developing these systems, based on year of establishment, company size and geographical location.
Chapter 6 provides a detailed competitiveness analysis of single-cell sequencing technologies based on several relevant parameters, such as supplier power (based on company’s employee count and years of experience) and product related specifications (type of sequencing, type of services offered, throughput)
Chapter 7 includes detailed profiles of the companies offering single-cell sequencing services, featuring a brief overview of the company, recent developments and an informed future outlook.
Chapter 8 includes detailed profiles of the companies offering single-cell sequencing platforms and technologies, featuring a brief overview of the company, its financial information (if available), proprietary platform(s), recent developments and an informed future outlook.
Chapter 9 presents an in-depth analysis of the various patents that have been filed / granted related to single-cell sequencing, based on key parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, and type of applicant, highlighting the leading industry / non-industry players (in terms of the size of intellectual property portfolio). It also features a patent benchmarking and valuation analysis.
Chapter 10 provides a detailed study of the various grants that have been awarded to research institutes engaged in projects related to single-cell sequencing, between 2016 and 2020, including an analysis based on multiple parameters, such as year of grant award, grant amount, focus area, activity code, support period, funding mechanism, funding institute center, type of recipient organization, popular recipient organizations and prominent program officers.
Chapter 11 provides an analysis of various developments / recent trends related to single-cell sequencing, offering insights on [A] partnerships and collaborations established within the industry, [B] funding and investments, and [C] recent product launches related to single-cell sequencing.
Chapter 12 presents a detailed market forecast, highlighting the future potential of the single-cell sequencing services and technologies market till the year 2030. The chapter features the likely distribution of the opportunity across different [A] key market segments (services and technologies), [B] type of system (sequencing and workflow instruments), [C] end-user (pharmaceutical companies, academic and research institutions and other end-users), [D] area of application (diagnostics, drug discovery, precision medicine and others) and [E]geographical regions (North America, Europe, Asia-Pacific and rest of the world).
Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.
Chapter 14 is a collection of executive insight(s) of the discussion(s) that were held with key stakeholder(s) in this market.
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research and Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Single-Cell Sequencing
3.2.1. Comparison of Bulk RNA and Single-cell RNA Sequencing
3.3. Applications of Single-cell Sequencing
3.3.1. In Cancer Research
3.3.2. In Clinical Diagnostics
3.3.3. In Drug Discovery
3.3.4. In Embryology
3.3.5. In Immunology
3.3.6. In Microbiology
3.3.7. In Neurology
3.3.8. In Organ Development
3.4. Challenges Associated with Single-cell Sequencing
3.4.1. Data Pre-processing
3.4.2. Low Capturing Efficiency
3.4.3. Rigid and Undefined Statistical Frameworks
3.4.4. Lack of Appropriate Quality Control Systems
3.5. Future Perspectives
4. MARKET LANDSCAPE: SINGLE-CELL SEQUENCING SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Single-cell Sequencing Service Providers: Market Landscape of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Sequencing Method Used
4.2.5. Analysis by Type of Service Offered
4.2.6. Analysis by Type of Library Preparation System Used
4.2.7. Analysis by Type of Sequencing System Used
4.3. Single-cell Sequencing Service Providers: Market Landscape of Non-Industry Players
4.3.1. Analysis by Location of Organization
4.3.2. Analysis by Sequencing Method Used
4.3.3. Analysis by Type of Service Offered
4.3.4. Analysis by Type of Library Preparation System Used
4.3.5. Analysis by Type of Sequencing System Used
5. MARKET LANDSCAPE: SINGLE-CELL SEQUENCING TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Single-cell Sequencing Systems and Technologies: Market Landscape of Workflow Instruments
5.2.1. Analysis by Target Nucleic Acid
5.2.2. Analysis by Type of Application
5.2.3. Analysis by Throughput
5.3. Single-cell Sequencing Systems and Technologies: Developer Landscape
5.3.4. Analysis by Year of Establishment
5.3.5. Analysis by Company Size
5.3.6. Analysis by Location of Headquarters
5.4. Single-cell Sequencing Systems and Technologies: Market Landscape of Sequencing Instruments
5.4.1. Analysis by Type of Application
5.4.2. Analysis by Maximum Output
5.4.3. Analysis by Maximum Read Length
5.4.4. Analysis by System Efficiency
5.4.5. Analysis by Sequencing Chemistry
5.5. Single-cell Sequencing Systems and Technologies: Developer Landscape
5.5.6. Analysis by Year of Establishment
5.5.7. Analysis by Company Size
5.5.8. Analysis by Location of Headquarters
6. SINGLE-CELL SEQUENCING TECHNOLOGIES: COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Parameters and Methodology
6.3. Competitiveness Analysis: Single-cell Workflow Instruments
6.4. Competitiveness Analysis: Single-cell Sequencing Instruments
7. COMPANY PROFILES: SINGLE-CELL SEQUENCING SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Active Motif
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook
7.3. Admera Health
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook
7.4. Annoroad Genomics
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook
7.5. BGI Genomics
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook
7.6. CD Genomics
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook
7.7. MedGenome
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook
7.8. Quick Biology
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook
7.9. SingulOmics
7.9.1. Company Overview
7.9.2. Recent Developments and Future Outlook
8. COMPANY PROFILES: SINGLE CELL SEQUENCING TECHNOLOGY PROVIDERS
8.1. 10x Genomics
8.1.1. Company Overview
8.1.2. Financial Information
8.1.3. Product Portfolio
8.1.3.1. 10x Chromium
8.1.4. Recent Developments and Future Outlook
8.2. Cell Microsystems
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.2.1. Cellraft AIR
8.3. Fluidigm
8.3.1. Company Overview
8.3.2. Financial information
8.3.3. Product Portfolio
8.3.3.1. Fluidigm C1
8.3.4. Recent Developments and Future Outlook
8.4. Illumina
8.4.2. Financial Information
8.4.3. Product Portfolio
8.4.3.1. MiSeq Series
8.4.3.2. Nextseq Series
8.4.3.3. NovaSeq 6000 System
8.4.4. Recent Developments and Future Outlook
8.5. Mission Bio
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.2.1. Tapestri
8.5.3. Recent Developments and Future Outlook
8.6. Oxford Nanopore Technologies
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Product Portfolio
8.6.3.1. MinIon Systems
8.6.3.2. PromethIon Systems
8.6.4. Recent Developments and Future Outlook
9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Single-cell Sequencing: Patent Analysis
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Geographical Location
9.3.3. Analysis by CPC Symbols
9.3.4. Word Cloud: Emerging Focus Areas
9.3.5. Analysis by Type of Applicant
9.3.6. Leading Players: Analysis by Number of Patents
9.4. Single-cell Sequencing: Benchmarking Analysis
9.4.1. Analysis by Patent Characteristics
9.4.2. Analysis by Geography
9.5. Single-cell Sequencing: Patent Valuation Analysis
10. ACADEMIC GRANT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Single-cell Sequencing: Analysis of Academic Grants
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Grant Amount
10.3.3. Analysis by Focus Area
10.3.4. Analysis by Activity Code
10.3.5. Analysis by Support Period
10.3.6. Analysis by Funding Mechanism
10.3.7. Analysis by Funding Institute Center
10.3.8. Analysis by Type of Recipient Organization
10.3.9. Popular Recipient Organizations: Analysis by Number of Grants
10.3.10. Prominent Program Officers: Analysis by Number of Grants
11. RECENT DEVELOPMENTS: SINGLE-CELL SEQUENCING MARKET
11.1. Chapter Overview
11.2. Single-cell Sequencing: Recent Partnerships
11.2.1. Partnership Models
11.2.2. Analysis by Year of Partnership
11.2.3. Analysis by Type of Agreement
11.2.4. Analysis by Focus Area of Partnership
11.2.5. Regional Analysis by Number of Partnerships
11.3. Single-cell Sequencing: Recent Funding and Investments
11.3.1. Analysis by Year of Funding
11.3.3. Analysis by Type of Funding
11.3.2. Analysis by Amount Invested
11.3.4. Most Active Players: Analysis by Amount Invested
11.3.5. Most Active Investors: Analysis by Number of Funding Instances
11.4. Single-cell Sequencing: Recent Product Launches
11.4.1. Analysis by Year of Product Launch
11.4.2. Analysis by Type of Product
11.4.3. Analysis by Focus Area
11.4.4. Most Active Players: Analysis by Number of Launches
12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Overall Single-cell Sequencing Services and Technologies Market Opportunity,
12.4. Single-cell Sequencing Services and Technologies Market Opportunity Across Key Market Segments, 2020-2030
12.5. Single-cell Sequencing Services and Technologies Market Opportunity:
12.6. Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by End-User 2020 and 2030
12.7. Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Area of Application, 2020 and 2030
12.8. Single-cell Sequencing Services and Technologies Market Opportunity: Geographical Distribution, 2020 and 2030
12.8.1. Single-cell Sequencing Services and Technologies Market Opportunity in North America, 2020-2030
12.8.1.1. Single-cell Sequencing Services and Technologies Market Opportunity in North America Across Key Market Segments, 2020-2030
12.8.1.1.1. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Service Providers, 2020-2030
12.8.1.1.2. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Technology Providers, 2020-2030
12.8.1.2. Single-cell Sequencing Services and Technologies Market Opportunity in North America: Distribution by End-Users, 2020-2030
12.8.1.2.1. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Academic and Research Institutions, 2020-2030
12.8.1.2.2. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Pharmaceutical Companies, 2020-2030
12.8.1.2.3. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other End-Users, 2020-2030
12.8.1.3. Single-cell Sequencing Services and Technologies Market Opportunity in North America: Distribution by Area of Application, 2020-2030
12.8.1.3.1. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Diagnostics, 2020-2030
12.8.1.3.2. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Drug Discovery, 2020-2030
12.8.1.3.3. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Precision Medicine, 2020-2030
12.8.1.3.4. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other Applications, 2020-2030
12.8.2. Single-cell Sequencing Services and Technologies Market Opportunity in Europe, 2020-2030
12.8.2.1. Single-cell Sequencing Services and Technologies Market Opportunity in Europe Across Key Market Segments, 2020-2030
12.8.2.1.1. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Service Providers, 2020-2030
12.8.2.1.2. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Technology Providers, 2020-2030
12.8.2.2. Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Distribution by End-Users, 2020-2030
12.8.2.2.1. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Academic and Research Institutions, 2020-2030
12.8.2.2.2. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Pharmaceutical Companies, 2020-2030
12.8.2.2.3. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other End-Users, 2020-2030
12.8.2.3. Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Distribution by Area of Application, 2020-2030
12.8.2.3.1. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Diagnostics, 2020-2030
12.8.2.3.2. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Drug Discovery, 2020-2030
12.8.2.3.3. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Precision Medicine, 2020-2030
12.8.2.3.4. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other Applications, 2020-2030
12.8.3. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific, 2020-2030
12.8.3.1. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific Across Key Market Segments, 2020-2030
12.8.3.1.1. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Service Providers, 2020-2030
12.8.3.1.2. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Technology Providers, 2020-2030
12.8.3.2. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Distribution by End-Users, 2020-2030
12.8.3.2.1. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030
12.8.3.2.2. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030
12.8.3.2.3. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other End-Users, 2020-2030
12.8.3.3. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Distribution by Area of Application, 2020-2030
12.8.3.3.1. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Diagnostics, 2020-2030
12.8.3.3.2. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Drug Discovery, 2020-2030
12.8.3.3.3. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Precision Medicine, 2020-2030
12.8.3.3.4. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other Applications, 2020-2030
12.8.4. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World, 2020-2030
12.8.4.1. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World Across Key Market Segments, 2020-2030
12.8.4.1.1. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Service Providers, 2020-2030
12.8.4.1.2. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Technology Providers, 2020-2030
12.8.4.2. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Distribution by End-Users, 2020-2030
12.8.4.2.1. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Academic and Research Institutions, 2020-2030
12.8.4.2.2. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Pharmaceutical Companies, 2020-2030
12.8.4.2.3. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other End-Users, 2020-2030
12.8.4.3. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Distribution by Area of Application, 2020-2030
12.8.4.3.1. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Diagnostics, 2020-2030
12.8.4.3.2. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Drug Discovery, 2020-2030
12.8.4.3.3. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Precision Medicine, 2020-2030
12.8.4.3.4. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other Applications, 2020-2030
13. CONCLUSION
13.1. Chapter Overview
13.2. Key Takeaways
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Genuity Science
14.2.1. Company Snapshot
14.2.2. Interview Transcript, Irene Blat, Senior Director of Data Products and Analytics
15. APPENDIX I: TABULATED DATA
Figure 3.1 Process of Single-cell Sequencing
Figure 3.2 Bulk RNA Sequencing versus scRNA Sequencing
Figure 3.3 Applications of Single-cell Sequencing
Figure 3.4 Challenges Associated with Single-cell Sequencing
Figure 4.1 Single-cell Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Single-cell Sequencing Service Providers (Industry Players): Distribution by Company Size
Figure 4.3 Single-cell Sequencing Service Providers (Industry Players): Distribution by Location of Headquarters
Figure 4.4 Single-cell Sequencing Service Providers (Industry Players): Distribution by Sequencing Method Used
Figure 4.5 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Service Offered
Figure 4.6 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Library Preparation System Used
Figure 4.7 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Sequencing System Used
Figure 4.8 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Location of Organization
Figure 4.9 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Sequencing Method Used
Figure 4.10 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Service Offered
Figure 4.11 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Library Preparation System Used
Figure 4.12 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Sequencing System Used
Figure 5.1 Single-cell Sequencing Workflow Instruments: Distribution by Targeted Nucleic Acid
Figure 5.2 Single-cell Sequencing Workflow Instruments: Distribution by Type of Application
Figure 5.3 Single-cell Sequencing Workflow Instruments: Distribution by Throughput
Figure 5.4 Single-cell Sequencing Workflow Instrument Providers: Distribution by Year of Establishment
Figure 5.5 Single-cell Sequencing Workflow Instrument Providers: Distribution by Company Size
Figure 5.6 Single-cell Sequencing Workflow Instrument Providers: Distribution by Location of Headquarters
Figure 5.7 Single-cell Sequencing Instruments: Distribution by Type of Application
Figure 5.8 Single-cell Sequencing Instruments: Distribution by Maximum Output
Figure 5.9 Single-cell Sequencing Instruments: Distribution by Maximum Read Length
Figure 5.10 Single-cell Sequencing Instruments: Distribution by System Efficiency
Figure 5.11 Single-cell Sequencing Instruments: Distribution by Sequencing Chemistry
Figure 5.12 Single-cell Sequencing Instrument Providers: Distribution by Year of Establishment
Figure 5.13 Single-cell Sequencing Instrument Providers: Distribution by Company Size
Figure 5.14 Single-cell Sequencing Instrument Providers: Distribution by Location of Headquarters
Figure 6.1 Platform Competitiveness Analysis: Single-cell Workflow Instruments (Peer Group I)
Figure 6.2 Platform Competitiveness Analysis: Single-cell Workflow Instruments (Peer Group II)
Figure 6.3 Platform Competitiveness Analysis: Single-cell Sequencing Instruments (Peer Group I)
Figure 6.4 Platform Competitiveness Analysis: Single-cell Sequencing Instruments (Peer Group II)
Figure 8.1 10x Genomics: Annual Revenues, 2017-Q2 2020 (USD Million)
Figure 8.2 Fluidigm: Annual Revenues, 2015-Q2 2020 (USD Million)
Figure 8.3 Illumina: Annual Revenues, 2013-Q2 2020 (USD Billion)
Figure 8.4 Illumina: Sequencing Systems Portfolio
Figure 8.5 Oxford Nanopore Technologies: Sequencing Systems Portfolio
Figure 9.1 Patent Analysis: Distribution by Patent Type
Figure 9.2 Patent Analysis: Cumulative Distribution by Publication Year, 2015-2020
Figure 9.3 Patent Analysis: Distribution by Geographical Location and Publication Year (Pre 2015- 2020)
Figure 9.4 Patent Analysis: Distribution by Patent Type and Publication Year
Figure 9.5 Patent Analysis: Distribution by Geographical Location
Figure 9.6 Patent Analysis: Distribution by Jurisdiction
Figure 9.7 Patent Analysis: Distribution by CPC Symbols
Figure 9.8 Patent Analysis: Emerging Focus Areas
Figure 9.9 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (Pre 2015-2019)
Figure 9.10 Leading Players: Distribution by Number of Patents
Figure 9.11 Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Classifications)
Figure 9.12 Patent Analysis: Benchmarking by International Patents
Figure 9.13 Patent Analysis: Distribution of Patents by Geographical Region and Patent Type
Figure 9.14 Single-cell Sequencing: Age of Patents
Figure 9.15 Patent Analysis: Valuation Analysis
Figure 10.1 Academic Grant Analysis: Cumulative Year-wise Trend, 2016-2020
Figure 10.2 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 10.3 Academic Grant Analysis: Distribution by Focus Area
Figure 10.4 Academic Grant Analysis: Distribution by Activity Code
Figure 10.5 Academic Grant Analysis: Distribution by Support Period
Figure 10.6 Academic Grant Analysis: Distribution by Funding Mechanism
Figure 10.7 Academic Grant Analysis: Distribution of Funding Institute Center by Support Year and Number of Grants
Figure 10.8 Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 10.9 Popular Recipient Organizations: Distribution across States in the US
Figure 10.10 Popular Recipient Organizations: Distribution by Number of Grants
Figure 10.11 Popular Recipient Organizations: Distribution by Amount Awarded (USD Million)
Figure 10.12 Prominent Program Officers: Distribution by Number of Grants
Figure 11.1 Recent Partnerships: Distribution by Year of Partnership
Figure 11.2 Recent Partnerships: Distribution by Type of Agreement
Figure 11.3 Recent Partnerships: Distribution by Focus Area of Partnership
Figure 11.4 Recent Partnerships: Regional Distribution
Figure 11.5 Recent Investments: Distribution by Year of Funding
Figure 11.6 Recent Investments: Distribution by Type of Funding
Figure 11.7 Recent Investments: Distribution by Amount Invested (USD Million)
Figure 11.8 Most Active Players: Distribution by Amount Invested
Figure 11.9 Most Active Investors: Distribution by Number of Funding Instances
Figure 11.10 Recent Product Launches: Distribution by Year of Product Launch
Figure 11.11 Recent Product Launches: Distribution by Type of Product
Figure 11.12 Recent Product Launches: Distribution by Focus Area
Figure 11.13 Most Active Players: Distribution by Number of Product Launches
Figure 12.1 Overall Single-cell Sequencing Services and Technologies Market Opportunity, 2020-2030 (USD Million)
Figure 12.2 Single-cell Sequencing Services and Technologies Market Opportunity Across Key Market Segments, 2020 and 2030 (USD Million)
Figure 12.3 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Type of System, 2020 and 2030 (USD Million)
Figure 12.4 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by End-User, 2020 and 2030 (USD Million)
Figure 12.5 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Area of Application, 2020 and 2030 (USD Million)
Figure 12.6 Single-cell Sequencing Services and Technologies Market Opportunity: Geographical Distribution, 2020 and 2030 (USD Million)
Figure 12.7 Single-cell Sequencing Services and Technologies Market Opportunity in North America, 2020-2030 (USD Million)
Figure 12.8 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Service Providers, 2020-2030 (USD Million)
Figure 12.9 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Technology Providers, 2020-2030 (USD Million)
Figure 12.10 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Figure 12.11 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Figure 12.12 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Other End-Users, 2020-2030 (USD Million)
Figure 12.13 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Diagnostics, 2020-2030 (USD Million)
Figure 12.14 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Drug Discovery, 2020-2030 (USD Million)
Figure 12.15 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Precision Medicine, 2020-2030 (USD Million)
Figure 12.16 Single-cell Sequencing Services and Technologies Market Opportunity in North America: Share of Other Applications, 2020-2030 (USD Million)
Figure 12.17 Single-cell Sequencing Services and Technologies Market Opportunity in Europe, 2020-2030 (USD Million)
Figure 12.18 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Service Providers, 2020-2030 (USD Million)
Figure 12.19 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Technology Providers, 2020-2030 (USD Million)
Figure 12.20 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Figure 12.21 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Figure 12.22 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Other End-Users, 2020-2030 (USD Million)
Figure 12.23 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Diagnostics, 2020-2030 (USD Million)
Figure 12.24 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Drug Discovery, 2020-2030 (USD Million)
Figure 12.25 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Precision Medicine, 2020-2030 (USD Million)
Figure 12.26 Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Other Applications, 2020-2030 (USD Million)
Figure 12.27 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific, 2020-2030 (USD Million)
Figure 12.28 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Service Providers, 2020-2030 (USD Million)
Figure 12.29 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Technology Providers, 2020-2030 (USD Million)
Figure 12.30 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Figure 12.31 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Figure 12.32 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Other End-Users, 2020-2030 (USD Million)
Figure 12.33 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Diagnostics, 2020-2030 (USD Million)
Figure 12.34 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Drug Discovery, 2020-2030 (USD Million)
Figure 12.35 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Precision Medicine, 2020-2030 (USD Million)
Figure 12.36 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Other Applications, 2020-2030 (USD Million)
Figure 12.37 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World, 2020-2030 (USD Million)
Figure 12.38 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Service Providers, 2020-2030 (USD Million)
Figure 12.39 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Technology Providers, 2020-2030 (USD Million)
Figure 12.40 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Figure 12.41 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Figure 12.42 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Other End-Users, 2020-2030 (USD Million)
Figure 12.43 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Diagnostics, 2020-2030 (USD Million)
Figure 12.44 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Drug Discovery, 2020-2030 (USD Million)
Figure 12.45 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Precision Medicine, 2020-2030 (USD Million)
Figure 12.46 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Other Applications, 2020-2030 (USD Million)
Table 3.1 Comparison of Bulk RNA Sequencing and scRNA Sequencing
Table 4.1 Single-cell Sequencing Service Providers: List of Industry Players
Table 4.2 Single-cell Sequencing Service Providers (Industry Players): Information on Sequencing Method, Turn Around Time and Sample Used
Table 4.3 Single-cell Sequencing Service Providers (Industry Players): Information on Type of Service Offered, Library Preparation System Used and Sequencing System Used
Table 4.4 Single-cell Sequencing Providers: List of Non-Industry Players
Table 4.5 Single-cell Sequencing Service Providers (Non-Industry Players): Information on Sequencing Method Used, Turn Around Time and Price of Services
Table 4.6 Single-cell Sequencing Service Providers (Non-Industry Players): Information on Type of Service Offered, Library Preparation System Used and Sequencing System Used
Table 4.7 Additional List of Companies
Table 5.1 Single-cell Sequencing Workflow Instruments: Information on Name of Developer, Target Nucleic Acid and System Throughput
Table 5.2 Single-cell Sequencing Workflow Instruments: Information on Type of Application and Analytical Software Used
Table 5.3 List of Single-cell Sequencing Workflow Instrument Providers
Table 5.4 Single-cell Sequencing Instruments: Information on Type of Application, Run Time, Maximum Output and Output Range
Table 5.5 Single-cell Sequencing Instruments: Information on Maximum Reads per Run, Reads per Run, Maximum Read Length, Maximum Quality Score, Sequencing Chemistry and Cost of Instrument
Table 5.6 List of Single-cell Sequencing Instrument Providers
Table 7.1 Single-cell Sequencing Service Providers: List of Profiled Companies
Table 7.2 Active Motif: Company Snapshot
Table 7.3 Admera Health: Company Snapshot
Table 7.4 Admera Health: Recent Developments and Future Outlook
Table 7.5 Annoroad Genomics: Company Snapshot
Table 7.6 Annoroad Genomics: Recent Developments and Future Outlook
Table 7.7 BGI Genomics: Company Snapshot
Table 7.8 BGI Genomics: Recent Developments and Future Outlook
Table 7.9 CD Genomics: Company Snapshot
Table 7.10 CD Genomics: Recent Developments and Future Outlook
Table 7.11 MedGenome: Company Snapshot
Table 7.12 MedGenome: Recent Developments and Future Outlook
Table 7.13 Quick Biology: Company Snapshot
Table 7.14 Quick Biology: Recent Developments and Future Outlook
Table 7.15 SingulOmics: Company Snapshot
Table 8.1 10x Genomics: Company Snapshot
Table 8.2 10x Genomics: Recent Developments and Future Outlook
Table 8.3 Cell Microsystems: Company Snapshot
Table 8.4 Fluidigm: Company Snapshot
Table 8.5 Fluidigm: Recent Developments and Future Outlook
Table 8.6 Illumina: Company Snapshot
Table 8.7 Illumina: Recent Developments and Future Outlook
Table 8.8 Mission Bio: Company Snapshot
Table 8.9 Mission Bio: Recent Developments and Future Outlook
Table 8.10 Oxford Nanopore Technologies: Company Snapshot
Table 8.11 Oxford Nanopore Technologies: Recent Developments and Future Outlook
Table 9.1 Patent Analysis: CPC Symbols
Table 9.2 Patent Analysis: Most Popular CPC Symbols
Table 9.3 Patent Analysis: List of Top 10 CPC Symbols
Table 9.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 9.5 Patent Analysis: List of Relatively Higher Value Patents
Table 15.1 Single-cell Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Table 15.2 Single-cell Sequencing Service Providers (Industry Players): Distribution by Company Size
Table 15.3 Single-cell Sequencing Service Providers (Industry Players): Distribution by Location of Headquarters
Table 15.4 Single-cell Sequencing Service Providers (Industry Players): Distribution by Sequencing Method Used
Table 15.5 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Service Offered
Table 15.6 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Library Preparation System Used
Table 15.7 Single-cell Sequencing Service Providers (Industry Players): Distribution by Type of Sequencing System Used
Table 15.8 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Location of Organization
Table 15.9 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Sequencing Method Used
Table 15.10 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Types of Service Offered
Table 15.11 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Library Preparation System Used
Table 15.12 Single-cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Sequencing System Used
Table 15.13 Single-cell Sequencing Workflow Instruments: Distribution by Target Nucleic Acid
Table 15.14 Single-cell Sequencing Workflow Instruments: Distribution by Type of Application
Table 15.15 Single-cell Sequencing Workflow Instruments: Distribution by Throughput
Table 15.16 Single-cell Sequencing Workflow Instrument Providers: Distribution by Year of Establishment
Table 15.17 Single-cell Sequencing Workflow Instrument Providers: Distribution by Company Size
Table 15.18 Single-cell Sequencing Workflow Instrument Providers: Distribution by Location of Headquarters
Table 15.19 Single-cell Sequencing Instruments: Distribution by Type of Application
Table 15.20 Single-cell Sequencing Instruments: Distribution by Maximum Output
Table 15.21 Single-cell Sequencing Instruments: Distribution by Maximum Read Length
Table 15.22 Single-cell Sequencing Instruments: Distribution by System Efficiency
Table 15.23 Single-cell Sequencing Instruments: Distribution by Sequencing Chemistry
Table 15.24 Single-cell Sequencing Instrument Providers: Distribution by Year of Establishment
Table 15.25 Single-cell Sequencing Instrument Providers: Distribution by Company Size
Table 15.26 Single-cell Sequencing Instrument Providers: Distribution by Location of Headquarters
Table 15.27 10x Genomics: Annual Revenues, 2017-Q2 2020 (USD Million)
Table 15.28 Fluidigm: Annual Revenues, 2015-Q2 2020 (USD Million)
Table 15.29 Illumina: Annual Revenues, 2013-Q2 2020 (USD Billion)
Table 15.30 Patent Analysis: Distribution by Patent Type
Table 15.31 Patent Analysis: Cumulative Distribution by Publication Year, 2015-2020
Table 15.32 Patent Analysis: Distribution by Geographical Location and Publication Year (Pre 2015- 2020)
Table 15.33 Patent Analysis: Distribution by Patent Type and Publication Year
Table 15.34 Patent Analysis: Distribution by Geographical Location
Table 15.35 Patent Analysis: Distribution by Jurisdiction
Table 15.36 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (Pre 2015-2019)
Table 15.37 Leading Players: Distribution by Number of Patents
Table 15.38 Patent Analysis: Distribution of Patents by Geographical Region and Patent Type
Table 15.39 Single-cell Sequencing: Age of Patents
Table 15.40 Academic Grant Analysis: Cumulative Year-wise Trend, 2016-2020
Table 15.41 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 15.42 Academic Grant Analysis: Distribution by Activity Codes
Table 15.43 Academic Grant Analysis: Distribution by Support Period
Table 15.44 Academic Grant Analysis: Distribution by Funding Mechanism
Table 15.45 Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 15.46 Popular Recipient Organizations: Distribution by Number of Grants
Table 15.47 Popular Recipient Organizations: Distribution by Amount Awarded (USD Million)
Table 15.48 Prominent Program Officers: Distribution by Number of Grants
Table 15.49 Recent Partnerships: Distribution by Year of Partnership
Table 15.50 Recent Partnerships: Distribution by Type of Agreement
Table 15.51 Recent Partnerships: Distribution by Focus Area of Partnership
Table 15.52 Recent Partnerships: Regional Distribution
Table 15.53 Recent Investments: Distribution by Year of Funding
Table 15.54 Recent Investments: Distribution by Type of Funding
Table 15.55 Recent Investments: Distribution by Amount Invested (USD Million)
Table 15.56 Most Active Players: Distribution by Amount Invested
Table 15.57 Most Active Investors: Distribution by Number of Funding Instances
Table 15.58 Recent Product Launches: Distribution by Year of Product Launch
Table 15.59 Recent Product Launches: Distribution by Type of Product
Table 15.60 Recent Product Launches: Distribution by Focus Area
Table 15.61 Most Active Players: Distribution by Number of Product Launches
Table 15.62 Overall Single-cell Sequencing Services and Technologies Market Opportunity, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.63 Single-cell Sequencing Services and Technologies Market Opportunity Across Key Market Segments, 2020 and 2030 (USD Million)
Table 15.64 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Type of System, 2020 and 2030 (USD Million)
Table 15.65 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by End-User 2020 and 2030 (USD Million)
Table 15.66 Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Area of Application, 2020 and 2030 (USD Million)
Table 15.67 Single-cell Sequencing Services and Technologies Market Opportunity: Geographical Distribution, 2020 and 2030 (USD Million)
Table 15.68 Single-cell Sequencing Services and Technologies Market Opportunity in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.69 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Service Providers, 2020-2030 (USD Million)
Table 15.70 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Technology Providers, 2020-2030 (USD Million)
Table 15.71 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Table 15.72 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Table 15.73 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other End-Users, 2020-2030 (USD Million)
Table 15.74 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Diagnostics, 2020-2030 (USD Million)
Table 15.75 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Drug Discovery, 2020-2030 (USD Million)
Table 15.76 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Precision Medicine, 2020-2030 (USD Million)
Table 15.77 Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other Applications, 2020-2030 (USD Million)
Table 15.78 Single-cell Sequencing Services and Technologies Market Opportunity in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.79 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Service Providers, 2020-2030 (USD Million)
Table 15.80 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Technology Providers, 2020-2030 (USD Million)
Table 15.81 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Table 15.82 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Table 15.83 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other End-Users, 2020-2030 (USD Million)
Table 15.84 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Diagnostics, 2020-2030 (USD Million)
Table 15.85 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Drug Discovery, 2020-2030 (USD Million)
Table 15.86 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Precision Medicine, 2020-2030 (USD Million)
Table 15.87 Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other Applications, 2020-2030 (USD Million)
Table 15.88 Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.89 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Service Providers, 2020-2030 (USD Million)
Table 15.90 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Technology Providers, 2020-2030 (USD Million)
Table 15.91 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Table 15.92 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Table 15.93 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other End-Users, 2020-2030 (USD Million)
Table 15.94 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Diagnostics, 2020-2030 (USD Million)
Table 15.95 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Drug Discovery, 2020-2030 (USD Million)
Table 15.96 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Precision Medicine, 2020-2030 (USD Million)
Table 15.97 Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other Applications, 2020-2030 (USD Million)
Table 15.98 Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.99 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Service Providers, 2020-2030 (USD Million)
Table 15.100 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Technology Providers, 2020-2030 (USD Million)
Table 15.101 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Table 15.102 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Table 15.103 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other End-Users, 2020-2030 (USD Million)
Table 15.104 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Diagnostics, 2020-2030 (USD Million)
Table 15.105 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Drug Discovery, 2020-2030 (USD Million)
Table 15.106 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Precision Medicine, 2020-2030 (USD Million)
Table 15.107 Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other Applications, 2020-2030 (USD Million)
The following companies and organizations have been included in the report: